These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

566 related items for PubMed ID: 22641474

  • 1. Impact of sirolimus and tacrolimus on mortality and graft loss in liver transplant recipients with or without hepatitis C virus: an analysis of the Scientific Registry of Transplant Recipients Database.
    Watt KD, Dierkhising R, Heimbach JK, Charlton MR.
    Liver Transpl; 2012 Sep; 18(9):1029-36. PubMed ID: 22641474
    [Abstract] [Full Text] [Related]

  • 2. Canadian national retrospective chart review comparing the long term effect of cyclosporine vs. tacrolimus on clinical outcomes in patients with post-liver transplantation hepatitis C virus infection.
    Yoshida EM, Lilly LB, Marotta PJ, Mason AL, Bilodeau M, Vaillancourt M.
    Ann Hepatol; 2013 Sep; 12(2):282-93. PubMed ID: 23396740
    [Abstract] [Full Text] [Related]

  • 3. Outcome of recurrent hepatitis C virus after liver transplantation in a randomized trial of tacrolimus monotherapy versus triple therapy.
    Manousou P, Samonakis D, Cholongitas E, Patch D, O'Beirne J, Dhillon AP, Rolles K, McCormick A, Hayes P, Burroughs AK.
    Liver Transpl; 2009 Dec; 15(12):1783-91. PubMed ID: 19938143
    [Abstract] [Full Text] [Related]

  • 4. A retrospective study of conversion from tacrolimus-based to sirolimus-based immunosuppression in orthotopic liver transplant recipients.
    Yu S, He X, Yang L, Ma Y, Zhu X, Ju W, Huang J.
    Exp Clin Transplant; 2008 Jun; 6(2):113-7. PubMed ID: 18816237
    [Abstract] [Full Text] [Related]

  • 5. Impact of immunosuppression and acute rejection on recurrence of hepatitis C: results of the National Institute of Diabetes and Digestive and Kidney Diseases Liver Transplantation Database.
    Charlton M, Seaberg E.
    Liver Transpl Surg; 1999 Jul; 5(4 Suppl 1):S107-14. PubMed ID: 10431024
    [Abstract] [Full Text] [Related]

  • 6. Kidney transplantation in hepatitis C-positive recipients: does type of induction influence outcomes?
    Sureshkumar KK, Thai NL, Marcus RJ.
    Transplant Proc; 2012 Jun; 44(5):1262-4. PubMed ID: 22663997
    [Abstract] [Full Text] [Related]

  • 7. Better actual 10-year renal transplant outcomes of 80% reduced cyclosporine exposure with sirolimus base therapy compared with full cyclosporine exposure without or with concomittant sirolimus treatment.
    Pliszczynski J, Kahan BD.
    Transplant Proc; 2011 Dec; 43(10):3657-68. PubMed ID: 22172822
    [Abstract] [Full Text] [Related]

  • 8. Interleukin-2 receptor antibody does not reduce rejection risk in low immunological risk or tacrolimus-treated intermediate immunological risk renal transplant recipients.
    Lim WH, Chadban SJ, Campbell S, Dent H, Russ GR, McDonald SP.
    Nephrology (Carlton); 2010 Apr; 15(3):368-76. PubMed ID: 20470309
    [Abstract] [Full Text] [Related]

  • 9. End of the line for sirolimus in liver transplant recipients with hepatitis C virus?
    De Simone P, Saliba F, Fischer L.
    Liver Transpl; 2013 Feb; 19(2):236-7. PubMed ID: 23225519
    [No Abstract] [Full Text] [Related]

  • 10. Survival and hepatitis C virus recurrence after liver transplantation in HIV- and hepatitis C virus-coinfected patients: experience in a single center.
    Testillano M, Fernandez JR, Suarez MJ, Gastaca M, Bustamante J, Pijoan JI, Montejo M, Valdivieso A, Ruiz P, Gonzalez J, Ortiz de Urbina J.
    Transplant Proc; 2009 Apr; 41(3):1041-3. PubMed ID: 19376421
    [Abstract] [Full Text] [Related]

  • 11. Influence of immunosuppression and effect of hepatitis C virus on new onset of diabetes mellitus in liver transplant recipients.
    Sánchez-Pérez B, Aranda Narváez JM, Santoyo Santoyo J, Fernández-Aguilar JL, Suárez Muñoz MA, González-Sánchez AJ, Pérez Daga JA, Ramírez Plaza CP, Carrasco Campos J, Jiménez Mazure C, Becerra Ortíz R.
    Transplant Proc; 2008 Nov; 40(9):2994-6. PubMed ID: 19010171
    [Abstract] [Full Text] [Related]

  • 12. Association of Baseline Viral Serology and Sirolimus Regimens With Kidney Transplant Outcomes: A 14-Year Registry-Based Cohort Study in the United States.
    Santos AH, Casey MJ, Xuerong W, Womer KL.
    Transplantation; 2017 Feb; 101(2):377-386. PubMed ID: 28121742
    [Abstract] [Full Text] [Related]

  • 13. The impact of early corticosteroid withdrawal on graft survival in liver transplant recipients.
    Meadows HB, Taber DJ, Pilch NA, Tischer SM, Baliga PK, Chavin KD.
    Transplant Proc; 2012 Jun; 44(5):1323-8. PubMed ID: 22664009
    [Abstract] [Full Text] [Related]

  • 14. Primary immunosuppression and outcome differences after heart transplantation: tacrolimus versus cyclosporine.
    Castel MA, Farrero M, Vallejos I, Cardona M, Regueiro A, Pérez-Villa F.
    Transplant Proc; 2011 Jun; 43(6):2244-6. PubMed ID: 21839245
    [Abstract] [Full Text] [Related]

  • 15. Effect of chronic viral hepatitis on graft survival in Saudi renal transplant patients.
    Mitwalli AH, Alam A, Al-Wakeel J, Al Suwaida K, Tarif N, Schaar TA, Al Adbha B, Hammad D.
    Nephron Clin Pract; 2006 Jun; 102(2):c72-80. PubMed ID: 16244496
    [Abstract] [Full Text] [Related]

  • 16. Use of tacrolimus and the development of posttransplant diabetes mellitus: a Brazilian single-center, observational study.
    Gnatta D, Keitel E, Heineck I, Cardoso BD, Rodrigues AP, Michel K, Garcia VD.
    Transplant Proc; 2010 Mar; 42(2):475-8. PubMed ID: 20304169
    [Abstract] [Full Text] [Related]

  • 17. Recurrent hepatitis C posttransplant: early preservation injury may predict poor outcome.
    Watt KD, Lyden ER, Gulizia JM, McCashland TM.
    Liver Transpl; 2006 Jan; 12(1):134-9. PubMed ID: 16382465
    [Abstract] [Full Text] [Related]

  • 18. Conversion from calcineurin inhibitors to sirolimus maintenance therapy in renal allograft recipients: 24-month efficacy and safety results from the CONVERT trial.
    Schena FP, Pascoe MD, Alberu J, del Carmen Rial M, Oberbauer R, Brennan DC, Campistol JM, Racusen L, Polinsky MS, Goldberg-Alberts R, Li H, Scarola J, Neylan JF, Sirolimus CONVERT Trial Study Group.
    Transplantation; 2009 Jan 27; 87(2):233-42. PubMed ID: 19155978
    [Abstract] [Full Text] [Related]

  • 19. The absence of chronic rejection in pediatric primary liver transplant patients who are maintained on tacrolimus-based immunosuppression: a long-term analysis.
    Jain A, Mazariegos G, Pokharna R, Parizhskaya M, Kashyap R, Kosmach-Park B, Smith A, Fung JJ, Reyes J.
    Transplantation; 2003 Apr 15; 75(7):1020-5. PubMed ID: 12698091
    [Abstract] [Full Text] [Related]

  • 20. Sirolimus: more cause for alarm?
    Agarwal PD, Lucey MR.
    Liver Transpl; 2012 Sep 15; 18(9):1003-4. PubMed ID: 22639401
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 29.